Cover Image
市場調查報告書

多發性骨髓瘤(柯勒病):開發中產品分析

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229718
出版日期 內容資訊 英文 1198 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤(柯勒病):開發中產品分析 Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 1198 Pages
簡介

所謂多發性骨髓瘤是惡性漿細胞在骨髓內部增殖,並產生異常大量特殊蛋白質的癌症。其病因至今不明。高齡者是主要發病者。主要症狀有貧血症及出血、神經損傷、皮膚病變、骨頭壓痛、疼痛、腎功能衰竭等。主要治療方法有化療及放射療法、免疫抑制劑、外科手術等。

本報告提供全球各國治療多發性骨髓瘤(柯勒病)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

多發性骨髓瘤概要

治療藥的開發

  • 多發性骨髓瘤開發中產品:概要
  • 多發性骨髓瘤開發中產品:比較分析

各企業開發中的多發性骨髓瘤治療藥

大學/研究機關研究中的多發性骨髓瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

多發性骨髓瘤治療藥:開發中的產品一覽(各企業)

多發性骨髓瘤治療藥:研究中的產品一覽(各大學/研究機關)

多發性骨髓瘤開發治療藥的企業

多發性骨髓瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

多發性骨髓瘤治療藥:暫停開發的產品

多發性骨髓瘤治療藥:中止開發的產品

多發性骨髓瘤相關產品的開發里程碑

  • 最新消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9465IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 13, 67, 68, 1, 3, 130, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 10, 1, 21 and 5 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Myeloma (Kahler Disease) - Overview
  • Multiple Myeloma (Kahler Disease) - Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Galileo Research srl, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by HitGen LTD, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H1 2017
  • Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2017
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top